A. Decensi et al., Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer, CANC EPID B, 10(10), 2001, pp. 1047-1053
High insulin-like growth factor-I (IGF-I) levels are associated with an inc
reased risk of breast cancer in premenopausal women. Because the synthetic
retinoid fenretinide showed a beneficial effect on second breast cancers in
premenopausal women in a Phase III trial, we studied its long-term effects
on IGF-I levels. We measured, at yearly intervals for up to 5 years, the c
irculating levels of IGF-I, IGF binding protein (BP)-3, and their molar rat
io in 60 subjects less than or equal to 50 years of age and 60 subjects > 5
0 years of age allocated either to fenretinide or no treatment. In women le
ss than or equal to 50 years of age, measurements of IGF-H, IGFBP-1, and IG
FBP-2 were also performed. The associations between biomarkers and drug or
metabolite plasma concentrations were also investigated. All biomarkers wer
e relatively stable over 5 years in the control group. Compared with contro
ls and after adjustment for baseline, treatment with fenretinide for 1 year
induced the following changes: IGF-I, -13% [95% confidence interval (CI),
-25 to 1%] in women less than or equal to 50 years of age and -3% (95% CI,
-16 to 13%) in women >50 years of age; IGFBP-3, -4% (95% CI, -12 to 6%) in
both age groups; IGF-I:IGFBP-3 molar ratio, -11% (95% CI, -22 to 1%) in wom
en less than or equal to 50 years of age and 1% (95% CI, -11 to 16%) in wom
en > 50 years of age. These effects were apparently maintained for up to 5
years, although fewer samples were available as time progressed. No change
in other IGF components was observed. Drug and metabolite concentrations we
re negatively correlated with IGF-I and IGF-I:IGFBP-3 molar ratio in women
less than or equal to 50 years of age. Fenretinide induces a moderate decli
ne of IGF-I levels in women less than or equal to 50 years of age. The asso
ciation between IGF-I change and the reduction of second breast cancers in
premenopausal women warrants further study.